Open AccessP499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGRESS)
Author(s) -
Wei A. H.,
Carraway H. E.,
Taningco L.,
Laille E.,
Gong J.,
Prebet T.,
Lopes de Menezes D.,
Ravandi F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844884.73752.c1
Subject(s) - medicine , azacitidine , decitabine , venetoclax , hypomethylating agent , cytarabine , adverse effect , febrile neutropenia , oncology , myeloid leukemia , refractory (planetary science) , gastroenterology , leukemia , neutropenia , chemotherapy , chronic lymphocytic leukemia , gene expression , astrobiology , dna methylation , gene , biochemistry , chemistry , physics